commd7 Gene Expression in ALL

Not yet recruiting

• Conditions: ALL
• Interventions: Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

• Registration Number: NCT05592470
• Lead Sponsor: Assiut University

Brief Summary

* study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia.

* investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .

Detailed Description

Acute lymphoblastic leukemia (ALL) is a neoplastic disorder of lymphoid progenitor cells characterized by diverse cytogenetic and molecular abnormalities with peaks of prevalence for 2-5-year-old patients and those older than 50. Treatment strategies using risk-adapted chemotherapy cure more than 80% of childhood cases, but around 20 to 30% relapse developing serious complications including death.( 1) In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes.(2) The copper metabolism MURR1 domain (COMMD) protein family involved in tumor development and progression in several types of human cancer, but little is known about the function of COMMD proteins in hematological malignancy. (3) COMMD7, a member of the COMMD, which is located on chromosome 20q11.21, has been reported associated with tumor progression in human solid cancers \[4\]. COMMD7 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) cells, associated with poor prognosis. \[5\]. Another study revealed that COMMD7-overexpressed hepatocellular carcinoma (HCC) cells promoted the proliferation of naïve HCC cells (6) A recent study was found that high expression of COMMD7 is a potential biomarker for adverse outcomes and poor prognosis in AML. (7)

. However, to date, the expression of COMMD7 in acute lymphoblastic leukemia and its prognostic value remain unclear.

Study Timeline

• Status Verified: 2022-09
• Study First Submitted: 2022-10-20
• Study First Submitted QC: 2022-10-20
• Last Update Submitted: 2022-10-20
• Study First Posted: 2022-10-24
• Last Update Posted: 2022-10-24
• Study Start: 2022-11
• Primary Completion: 2024-04
• Study Completion: 2024-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

• Patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age.

Exclusion Criteria

• history of anti-neoplastic therapy, such as chemotherapy or radiotherapy.
• Any other types of cancers.
• Any clinically systemic acute or chronic inflammatory disease/s within one months.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PATEINTS	Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).	51 patients newly diagnosed with acute lymphoblastic leukemia
controls	Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).	51 normal persons

Primary Outcome Measures

Name	Time	Method
The expression pattern of COMMD7 gene in acute lymphoblastic leukemia	BASELINE	Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) TO DETECT EXPRESSION pattern in ALL

Secondary Outcome Measures

Name	Time	Method
Correlation between the expression level of COMMD7 GENE with other diagnostic parameters and prognosis in ALL	baseline